Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: Inj Teripratide 20 mcg in patiets with adynamic bone disease: Inj Teriperatide 20 mcg will be given in patients with adynamic bone disease. Bone turnover marker and BMD will be assesse
Sponsors
Department of Nephrology Command Hospital Air ForceIndian Air Force POAgram Bnagalore
Eligibility
Inclusion criteria
Inclusion criteria: Patients with chronic Kidney disease: Among dialysis patients, serum PTH <100 pg/mL, and among patients who are not on dialysis a PTH <65 pg/ml
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to teriparatide or any component of the formulation 2. Prior external beam or implant radiation therapy involving the skeleton 3. Bone metastases or history of skeletal malignancies 4. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of Teriparatide therapy for 6 months on bone formation markers(bone specific alkaline phosphatase) in adynamic bone disease due to chronic kidney diseaseTimepoint: Effect of Teriparatide therapy on bone formation markers(bone specific alkaline phosphatase) in adynamic bone disease due to chronic kidney disease at baseline, 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| i. Effect of Teriparatide therapy for 6 months on amino terminal propeptide of type I procollagen in adynamic bone disease due to chronic kidney disease ii. Effect of Teriparatide therapy for 6 months on bone mineral density in adynamic bone disease due to chronic kidney disease Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactVijoy Kumar Jha
COMMAND HOSPITAL AIR FORCE BANGALORE
Outcome results
None listed